957 NKTR-255+cetuximab in patients with solid tumors: interim safety and efficacy results from the phase 1b dose-escalation study by Manish Patel, Amita Patnaik, Ammar Sukari, Minal Barve, Mary Tagliaferri, Neha Dixit, Mehmet Altan, Christie Fanton, Xiaoli Wang, Sunil Sharma, Mario Marcondes, Sue Currie, Zachary Lee, Wildaliz Nieves, Haijun Ma, Lara Dunn, Patrick Cobb, Ari Rosenberg, Johnathan Zalevsky, Assuntina Sacco

438 A phase 1 trial of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck... by Michael Gibson, Ammar Sukari, Julie Bauman, Tanguy Seiwert, Barbara Burtness, Sara Pai, Cristina Rodriguez, Bonnie Glisson, Kenneth Pienta, Francis Worden, Lara Dunn, Douglas Adkins, Christine Chung, A Dimitrios Colevas, Lori Wirth, Nabil Saba, Laura Agensky, Matteo Levisetti, Reena Lynam, Steven Margossian, Raymond Moniz, Steve Quayle

428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs) by Marcus Butler, Rogerio Neves, Lisa Licitra, Israel Lowy, Zeynep Eroglu, Karl Lewis, Leonel Hernandez-Aya, Axel Hauschild, Emmanuel Okoye, Siyu Li, Jean-Francois Baurain, Oliver Bechter, Ketty Peris, Aleksandar Sekulic, Alexander Stratigos, Lara Dunn, Anne Lynn Chang, Michael Migden, Kosalai Mohan, Ebony Coates, Emily Ruiz, Frank Seebach, David Weinreich, George Yancopoulos, Timothy Bowler, Matthew Fury